FailedDiscontinued

Nemvaleukin alfa + pembrolizumab

Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer

MURAMural Oncology plc

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Nemvaleukin alfa + pembrolizumab
Development stage: Failed
Event type: Discontinued
Indication: Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer

Research summary

What is being tracked?

This catalyst tracks a Failed discontinued for Nemvaleukin alfa + pembrolizumab in Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

ARTISTRY-7. 3/11/25- Interim data readout in Late Q1/early Q2 2025. 3/25/25- Will not progress trial to final analysis

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source